Most cited papers from Nerviano Medical Sciences

Nerviano Medical Sciences

What are the most cited papers from Nerviano Medical Sciences?

The most cited paper from Nerviano Medical Sciences is "Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability" (Francesco Colotta, Paola Allavena, Antonio Sica et al., 2009), with 2,919 citations. Next come "Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction" (1,487) and "The target landscape of clinical kinase drugs" (905).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 144 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability Francesco Colotta, Paola Allavena, Antonio Sica et al. · Carcinogenesis	25 May 2009	2,919
2	Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction Marcella Martignoni, Geny M. M. Groothuis, Ruben de Kanter · Expert Opinion on Drug Metabolism & Toxicology	24 Nov 2006	1,487
3	The target landscape of clinical kinase drugs Susan Klaeger et al. · Science Open access	30 Nov 2017	905
4	Discovery of drug mode of action and drug repositioning from transcriptional responses Francesco Iorio, Roberta Bosotti, Emanuela Scacheri et al. · Proceedings of the National Academy of Sciences Open access	2 Aug 2010	858
5	The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia Ulf Klein, Marie Lia, Marta Crespo et al. · Cancer Cell Open access	2010	856
6	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Alexander Edward Dela Cruz Drilon et al. · Cancer Discovery Open access	9 Feb 2017	836
7	Apaf-1 is a transcriptional target for E2F and p53 Maria Cristina Moroni, Emma S. Hickman, Eros Lazzerini Denchi et al. · Nature Cell Biology	10 May 2001	593
8	WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability Claudio Dalvit, Gianpaolo Fogliatto, Albert Stewart et al. · Journal of Biomolecular NMR	Dec 2001	573
9	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway Carla Boccaccio, Margherita Andò, Luca Tamagnone et al. · Nature	1998	528
10	Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation Fabio Zuccotto, Elena Ardini, Elena Casale et al. · Journal of Medicinal Chemistry Open access	14 Dec 2009	524
11	Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents Monica Simeoni, Paolo Magni, Cristiano Cammia et al. · Cancer Research Open access	Feb 2004	513
12	Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water* Claudio Dalvit, Paolo Pevarello, Marco Tatò et al. · Journal of Biomolecular NMR	Sep 2000	476
13	Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death Paola Magnaghi et al. · Nature Chemical Biology	28 Jul 2013	393
14	The structure of P‐TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation Sonja Baumli, Graziano Lolli, E.D. Lowe et al. · The EMBO Journal Open access	19 Jun 2008	363
15	Crystal structure of the tetrameric Mad1–Mad2 core complex: implications of a ‘safety belt’ binding mechanism for the spindle checkpoint Lucia Sironi, Marina Mapelli, Stefan Knapp et al. · The EMBO Journal Open access	15 May 2002	325
16	Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications Elena Ardini et al. · Molecular Cancer Therapeutics Open access	3 Mar 2016	321
17	Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors Jay Aaron Bertrand, Sandrine Thieffine, Anna Vulpetti et al. · Journal of Molecular Biology	Oct 2003	318
18	FAT: a novel domain in PIK-related kinases Roberta Bosotti, Antonella Isacchi, Erik L. L. Sonnhammer · Trends in Biochemical Sciences Review	May 2000	312
19	Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor Maria Menichincheri et al. · Journal of Medicinal Chemistry Open access	22 Mar 2016	302
20	AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis Céline Candé, Nicola Vahsen, Ilektra Kouranti et al. · Oncogene	12 Jan 2004	275
21	A Model of Insulin Resistance and Nonalcoholic Steatohepatitis in Rats Gianluca Svegliati‐Baroni, C. Candelaresi, S. Saccomanno et al. · American Journal Of Pathology Open access	Sep 2006	256
22	Fluorine-NMR Experiments for High-Throughput Screening: Theoretical Aspects, Practical Considerations, and Range of Applicability Claudio Dalvit, Paul E. Fagerness, Daneen T. A. Hadden et al. · Journal of the American Chemical Society	24 May 2003	253
23	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer Andrea Sartore Bianchi et al. · JNCI Journal of the National Cancer Institute Open access	12 Nov 2015	247
24	PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer Patrizia Carpinelli et al. · Molecular Cancer Therapeutics	Dec 2007	244
25	NMR screening techniques in drug discovery and drug design Brian J. Stockman, Claudio Dalvit · Progress in Nuclear Magnetic Resonance Spectroscopy	Dec 2002	231
26	A Submarine Journey: The Pyrrole-Imidazole Alkaloids Barbara Forte, Beatrice Malgesini, Claudia Piutti et al. · Marine Drugs Open access	27 Nov 2009	229
27	Identification of Mcm2 Phosphorylation Sites by S-phase-regulating Kinases Alessia Montagnoli, Barbara Valsasina, Deborah H. Brotherton et al. · Journal of Biological Chemistry Open access	30 Jan 2006	229
28	A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response Gennaro Gambardella, Gaetano Viscido, Barbara Tumaini et al. · Nature Communications Open access	31 Mar 2022	218
29	A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity Alessia Montagnoli et al. · Nature Chemical Biology Open access	11 May 2008	218
30	Bombesin stimulates growth of human prostatic cancer cellsin vitro Mauro Bologna, Claudio Festuccia, Paola Muzi et al. · Cancer Open access	May 1990	217
31	A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL) Alberto Cesare Luigi Redaelli, Benjamin L. Laskin, Jennifer M. L. Stephens et al. · European Journal of Cancer Care ReviewOpen access	7 Feb 2005	217
32	Biochemical and pharmacogenetic dissection of human steroid 5??-reductase type II Nick M. Makridakis, Enrico di Salle, Juergen K. V. Reichardt · Pharmacogenetics	Jul 2000	214
33	Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study Silvia Mori et al. · American Journal of Hematology Open access	15 Jul 2015	212
34	Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase Riccardo Colombo, Marina Caldarelli, Milena Mennecozzi et al. · Cancer Research Open access	14 Dec 2010	207
35	The Full Oncogenic Activity of Ret/ptc2 Depends on Tyrosine 539, a Docking Site for Phospholipase Cγ Maria Grazia Borrello, Luisella Alberti, Elena Arighi et al. · Molecular and Cellular Biology Open access	May 1996	199
36	Thiol-peptide level and proteomic changes in response to cadmium toxicity in Oryza sativa L. roots Roberta Aina, Massimo Labra, Pietro Fumagalli et al. · Environmental and Experimental Botany	22 Jun 2006	199
37	The clinical and epidemiological burden of chronic lymphocytic leukaemia Alberto Cesare Luigi Redaelli, Benjamin L. Laskin, JM Stephens et al. · European Journal of Cancer Care Open access	14 Jun 2004	196
38	1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile Daniele Fancelli et al. · Journal of Medicinal Chemistry Open access	Nov 2006	192
39	Ligand- and substrate-based 19F NMR screening: Principles and applications to drug discovery Claudio Dalvit · Progress in Nuclear Magnetic Resonance Spectroscopy	27 Jul 2007	190
40	Inhibition of protein–protein interactions: The discovery of druglike β‐catenin inhibitors by combining virtual and biophysical screening Jean‐Yves Trosset, Claudio Dalvit, Stefan Knapp et al. · Proteins Structure Function and Bioinformatics	27 Mar 2006	184
41	Determination of the Affinity of Drugs toward Serum Albumin by Measurement of the Quenching of the Intrinsic Tryptophan Fluorescence of the Protein Dennis E. Van Epps, Thomas J. Raub, Valeria Rosaria Caiolfa et al. · Journal of Pharmacy and Pharmacology	1999	183
42	Complement C1q Is Dramatically Up-Regulated in Brain Microglia in Response to Transient Global Cerebral Ischemia Martin K.-H. Schäfer, Wilhelm Schwaeble, Claes Post et al. · The Journal of Immunology Open access	May 2000	177
43	Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters Fabrizio Tagliavini et al. · Science	16 May 1997	175
44	Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors Roberto Tiberio Bossi, Maria Beatrice Saccardo, Elena Ardini et al. · Biochemistry	13 Jul 2010	173
45	Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat Silvia Consalvi, Chiara Mozzetta, Paolo U. Bettica et al. · Molecular Medicine Open access	2013	169
46	A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs Shang‐Fan Yu, Bing Song Zheng, MaryAnn Go et al. · Clinical Cancer Research	3 Apr 2015	167
47	Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I Artur Gontarewicz, Stefan Balabanov, Gunhild Keller et al. · Blood	12 Feb 2008	166
48	Synthesis and Immunosuppressive Activity of Novel Prodigiosin Derivatives Roberto D’Alessio, Alberto Bargiotti, Orlando Carlini et al. · Journal of Medicinal Chemistry	17 May 2000	162
49	PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity Chiara Soncini, Patrizia Carpinelli, Laura M. Gianellini et al. · Clinical Cancer Research	Jul 2006	161
50	The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition Elena Ardini et al. · Molecular Oncology Open access	11 Jun 2014	159

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.